Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

thermo fisher scientific inc. - TMO

TMO

Close Chg Chg %
676.98 18.10 2.67%

Closed Market

695.08

+18.10 (2.67%)

Volume: 2.09M

Last Updated:

Nov 6, 2026, 3:59 PM EDT

Trade Now

Company Overview: thermo fisher scientific inc. - TMO

TMO Key Data

Open

$666.66

 Day Range

666.24 - 697.78

52 Week Range

435.27 - 712.17

 Market Cap

$261.64B

Shares Outstanding

370.52M

 Public Float

369.55M

Beta

0.84

 Rev. Per Employee

N/A

P/E Ratio

37.26

 EPS

$18.99

Yield

27.18%

 Dividend

$0.47

EX-DIVIDEND DATE

Sep 15, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

2.34M

  

TMO Performance

1 Week
 
 -0.32%
 
1 Month
 
 5.58%
 
3 Months
 
 16.96%
 
1 Year
 
 21.37%
 
5 Years
 
 12.64%
 

TMO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 29
Full Ratings ➔

About thermo fisher scientific inc. - TMO

Thermo Fisher Scientific Inc. offers products and services to customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of disease. The Analytical Instruments segment offers instruments and supporting consumables, software and services. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products to healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Biopharma Services segment offers outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. The company was founded in July 1956 and is headquartered in Waltham, MA.

TMO At a Glance

Thermo Fisher Scientific, Inc.
168 Third Avenue
Waltham, Massachusetts 02451
Phone 1-781-622-1000 Revenue 44.56B
Industry Medical Specialties Net Income 6.70B
Sector Health Technology 2025 Sales Growth 3.911%
Fiscal Year-end 12 / 2026 Employees 125,000
View SEC Filings

TMO Valuation

P/E Current 37.257
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 32.672
Price to Sales Ratio 4.916
Price to Book Ratio 4.082
Price to Cash Flow Ratio 28.02
Enterprise Value to EBITDA 22.357
Enterprise Value to Sales 5.609
Total Debt to Enterprise Value 0.163

TMO Efficiency

Revenue/Employee 356,448.00
Income Per Employee 53,624.00
Receivables Turnover 4.217
Total Asset Turnover 0.429

TMO Liquidity

Current Ratio 1.89
Quick Ratio 1.533
Cash Ratio 0.666

TMO Profitability

Gross Margin 41.101
Operating Margin 18.848
Pretax Margin 16.402
Net Margin 15.044
Return on Assets 6.456
Return on Equity 13.017
Return on Total Capital 7.111
Return on Invested Capital 7.87

TMO Capital Structure

Total Debt to Total Equity 76.497
Total Debt to Total Capital 43.342
Total Debt to Total Assets 37.025
Long-Term Debt to Equity 69.367
Long-Term Debt to Total Capital 39.302
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Thermo Fisher Scientific Inc. - TMO

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
44.91B 42.86B 42.88B 44.56B
Sales Growth
+14.55% -4.58% +0.05% +3.91%
Cost of Goods Sold (COGS) incl D&A
25.90B 25.66B 25.15B 26.24B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.38B 3.41B 3.11B 2.78B
Depreciation
986.00M 1.07B 1.16B 1.05B
Amortization of Intangibles
2.40B 2.34B 1.95B 1.73B
COGS Growth
+32.32% -0.93% -2.00% +4.34%
Gross Income
19.01B 17.19B 17.73B 18.31B
Gross Income Growth
-3.17% -9.56% +3.11% +3.30%
Gross Profit Margin
+42.33% +40.12% +41.34% +41.10%
2022 2023 2024 2025 5-year trend
SG&A Expense
10.49B 9.75B 10.07B 9.91B
Research & Development
1.47B 1.34B 1.39B 1.40B
Other SG&A
9.02B 8.41B 8.68B 8.52B
SGA Growth
+12.56% -7.04% +3.26% -1.50%
Other Operating Expense
- - - -
-
Unusual Expense
131.00M 496.00M 73.00M 298.00M
EBIT after Unusual Expense
8.39B 6.95B 7.59B 8.10B
Non Operating Income/Expense
167.00M 839.00M 1.10B 912.00M
Non-Operating Interest Income
272.00M 879.00M 1.08B 993.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
726.00M 1.49B 1.65B 1.70B
Interest Expense Growth
+35.45% +105.37% +10.93% +2.96%
Gross Interest Expense
726.00M 1.49B 1.65B 1.70B
Interest Capitalized
- - - -
-
Pretax Income
7.83B 6.30B 7.04B 7.31B
Pretax Income Growth
-11.38% -19.62% +11.73% +3.85%
Pretax Margin
+17.44% +14.70% +16.41% +16.40%
Income Tax
703.00M 284.00M 657.00M 547.00M
Income Tax - Current - Domestic
1.07B 378.00M 691.00M 528.00M
Income Tax - Current - Foreign
633.00M 1.21B 1.18B 658.00M
Income Tax - Deferred - Domestic
(683.00M) (653.00M) (1.14B) (418.00M)
Income Tax - Deferred - Foreign
(314.00M) (647.00M) (72.00M) (221.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
6.96B 5.96B 6.34B 6.72B
Minority Interest Expense
10.00M (40.00M) 3.00M 17.00M
Net Income
6.95B 6.00B 6.33B 6.70B
Net Income Growth
-10.03% -13.74% +5.67% +5.81%
Net Margin Growth
+15.47% +13.99% +14.77% +15.04%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
6.95B 6.00B 6.33B 6.70B
Preferred Dividends
- - - -
-
Net Income Available to Common
6.95B 6.00B 6.33B 6.70B
EPS (Basic)
17.7296 15.5311 16.5838 17.7825
EPS (Basic) Growth
-9.57% -12.40% +6.78% +7.23%
Basic Shares Outstanding
392.00M 386.00M 382.00M 377.00M
EPS (Diluted)
17.6396 15.451 16.5405 17.7354
EPS (Diluted) Growth
-9.35% -12.41% +7.05% +7.22%
Diluted Shares Outstanding
394.00M 388.00M 383.00M 378.00M
EBITDA
11.91B 10.85B 10.77B 11.18B
EBITDA Growth
-7.78% -8.85% -0.76% +3.79%
EBITDA Margin
+26.51% +25.32% +25.12% +25.09%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 761.72
Number of Ratings 29 Current Quarters Estimate 7.131
FY Report Date 12 / 2026 Current Year's Estimate 25.29
Last Quarter’s Earnings 6.68 Median PE on CY Estimate N/A
Year Ago Earnings 22.87 Next Fiscal Year Estimate 27.746
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 21 14 27 27
Mean Estimate 7.13 6.06 25.29 27.75
High Estimates 7.27 6.53 25.44 28.60
Low Estimate 7.00 5.64 25.15 27.02
Coefficient of Variance 0.86 3.54 0.25 1.42

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 20 20 20
OVERWEIGHT 4 4 4
HOLD 4 4 4
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Thermo Fisher Scientific Inc. - TMO

Date Name Shares Transaction Value
Sep 30, 2026 Scott M. Sperling Director 17,738 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 30, 2026 Karen S. Lynch Director 399 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 30, 2026 Jennifer M. Johnson Director 769 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 30, 2026 R. Alexandra Keith Director 1,378 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 30, 2026 Dion J. Weisler Director 2,847 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 27, 2026 Marc N. Casper Chairman & CEO; Director 124,099 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $625.41 per share 77,612,755.59
Aug 27, 2026 Marc N. Casper Chairman & CEO; Director 124,066 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $626.59 per share 77,738,514.94
Aug 27, 2026 Marc N. Casper Chairman & CEO; Director 123,987 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $628.01 per share 77,865,075.87
Aug 27, 2026 Marc N. Casper Chairman & CEO; Director 123,925 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $628.74 per share 77,916,604.50
Aug 27, 2026 Marc N. Casper Chairman & CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 27, 2026 Marc N. Casper Chairman & CEO; Director 124,200 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $309.63 per share 38,456,046.00
Mar 3, 2026 Gianluca Pettiti President & COO 25,451 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $521.11 per share 13,262,770.61
Mar 3, 2026 Mike Shafer Executive Vice President 22,557 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $521.11 per share 11,754,678.27
Mar 3, 2026 Mike Shafer Executive Vice President 22,809 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $521.11 per share 11,885,997.99
Mar 3, 2026 Mike Shafer Executive Vice President 23,275 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $521.11 per share 12,128,835.25
Mar 3, 2026 Stephen Williamson Retiring Sr. VP and CFO 32,499 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $521.11 per share 16,935,553.89
Mar 3, 2026 Stephen Williamson Retiring Sr. VP and CFO 32,746 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $521.11 per share 17,064,268.06
Mar 3, 2026 Michel Lagarde Executive Vice President 85,151 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $521.11 per share 44,373,037.61
Mar 3, 2026 Michel Lagarde Executive Vice President 85,511 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $521.11 per share 44,560,637.21
Mar 3, 2026 Lisa P. Britt Sr. VP and Chief HR Officer 14,784 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $521.11 per share 7,704,090.24

Thermo Fisher Scientific Inc. in the News